

Attorney Docket No.: ISPH-0767  
Inventors: Baker et al.  
Serial No.: 10/647,918  
Filing Date: August 26, 2003  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A method of treating an inflammatory disorder in an individual comprising administering to said individual an effective amount of an oligonucleotide up to 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumor necrosis factor- $\alpha$ .

Claim 2 (original): The method of claim 1, wherein said oligonucleotide inhibits the expression of said human tumor necrosis factor- $\alpha$  and comprises at least an 8 nucleobase portion of SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 39, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 149, SEQ ID NO: 157, SEQ ID NO: 264, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 290, SEQ ID NO: 297, SEQ ID NO: 299, SEQ ID NO: 315, SEQ ID NO: 334, SEQ ID NO: 418, SEQ ID NO: 423, SEQ ID NO: 425, SEQ ID NO: 427, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 435, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 441, SEQ ID NO: 455, SEQ ID NO:

Attorney Docket No.: ISPH-0767  
Inventors: Baker et al.  
Serial No.: 10/647,918  
Filing Date: August 26, 2003  
Page 3

457, SEQ ID NO: 458, SEQ ID NO: 460, SEQ ID NO: 463, SEQ ID NO:  
465, SEQ ID NO: 466, SEQ ID NO: 468, SEQ ID NO: 472, SEQ ID NO:  
474, SEQ ID NO: 475, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO:  
494 or SEQ ID NO: 496.

Claim 3 (original): The method of claim 1, wherein said antisense oligonucleotide is administered orally, topically or parenterally.

Claim 4 (original): The method of claim 1, wherein said inflammatory disorder is inflammatory bowel disease, Crohn's disease, colitis or rheumatoid arthritis.

Claim 5 (original): The method of claim 1, wherein said oligonucleotide comprises at least one modified intersugar linkage.

Claim 6 (original): The method of claim 4, wherein said intersugar linkage is a phosphorothioate linkage.

Claim 7 (original): The method of claim 1, wherein said oligonucleotide comprises at least one 2'-O-methoxyethyl modification.

Claim 8 (original): The method of claim 1, wherein said oligonucleotide comprises at least one 5-methyl cytidine.

Attorney Docket No.: ISPH-0767  
Inventors: Baker et al.  
Serial No.: 10/647,918  
Filing Date: August 26, 2003  
Page 4

Claim 9 (original): The method of claim 7, wherein every 2'-O-methoxyethyl modified cytidine residue is a 5-methyl cytidine.

Claim 10 (original): The method of claim 7, wherein every cytidine residue is a 5-methyl cytidine.

Claim 11 (original): The method of claim 1, wherein said modified intersugar linkage is a methylene(methylimino) intersugar linkage.

Claim 12 (new): The method of claim 2, wherein said oligonucleotide comprises at least an 8 nucleobase portion of SEQ ID NO: 432.

Claim 13 (new): The method of claim 12, wherein said oligonucleotide comprises SEQ ID NO: 432

Claim 14 (new): The method of claim 13, wherein said oligonucleotide consists of SEQ ID NO: 432.

Claim 15 (new): A method of treating an inflammatory disorder in an individual comprising administering to said individual an effective amount of an oligonucleotide consisting of SEQ ID NO: 432.

Attorney Docket No.: ISPH-0767  
Inventors: Baker et al.  
Serial No.: 10/647,918  
Filing Date: August 26, 2003  
Page 5

Claim 16 (new): The method of claim 15, wherein every internucleoside linkage in said oligonucleotide is a phosphodiester linkage.

Claim 17 (new): The method of claim 15, wherein nucleotides 1-5 and 16-20 of said oligonucleotide comprise a 2'-methoxyethoxy (2'-MOE) modification.

Claim 18 (new): The method of claim 15, wherein all cytidine bases in said oligonucleotide are 5-methylcytidines.

Claim 19 (new): An oligonucleotide complementary to a nucleic acid molecule encoding human TNF-alpha wherein said oligonucleotide inhibits the expression of said TNF-alpha and consists of SEQ ID NO: 432.

Claim 20 (new): The oligonucleotide of claim 19 wherein every internucleoside linkage in said oligonucleotide is a phosphodiester linkage.

Claim 21 (new): The oligonucleotide of claim 19 wherein nucleotides 1-5 and 16-20 of said oligonucleotide comprise a 2'-methoxyethoxy (2'-MOE) modification.

Claim 22 (new): The oligonucleotide of claim 19 wherein all cytidine bases in said oligonucleotide are 5-methylcytidines.

Attorney Docket No.: ISPH-0767  
Inventors: Baker et al.  
Serial No.: 10/647,918  
Filing Date: August 26, 2003  
Page 6

Claim 23 (new): A composition comprising the  
oligonucleotide of claim 19 and a pharmaceutically acceptable  
carrier or diluent.